Trial
NCT02967770
Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
Thomas Jefferson University; Sinai Health System; Virginia Mason Hospital/Medical Center; Cedars-Sinai Medical Center; George Mason University; Caris Life Sciences; Theranostics Health, Inc; Guardant Health, Inc.; Companion Diagnostics, Inc.
Condition
Metastatic Pancreatic Cancer
Intervention
Molecularly Tailored Second Line Therapy
Why stopped
Issues with patient recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-11